informed consent semaglutide consent form to Peptide Therapy Template Semaglutide Injection Intake Form |
Description
Ahdjoudj, S
Cell 164:337340
In the SURMOUNT-1 program summarized in the EMA product information, tirzepatide produced mean body-weight reductions of 16.0%, 21.4% and 22.5% at 72 weeks across the 5 mg, 10 mg and 15 mg groups, versus 2.4% with placebo
One such development is the utilization of semaglutide designed for the management of type 2 diabetes
These figures indicate a significant change in the amount of weight people can lose with this drug
